Table 2.
Frequency of autoantibodies in relationship to number of TAAs in mini-array
| Type of cancer | ||||||
|---|---|---|---|---|---|---|
| Antigen(s) | Breast 64 | Lung 56 | Colorectal 45 | Prostate 206 | Gastric 91 | HCC 65 |
| IMP1 | 5 (7·8)a | 4 (7·1) | 6 (13·3) | 18 (8·7) | 15 (16·5) | 10 (15·4) |
| IMP1 or p62 | 8 (12·5) | 15 (26·8) | 8 (17·8) | 64 (31·1) | 18 (19·8) | 15 (23·1) |
| IMP1 or p62 or Koc | 14 (21·9) | 19 (33·9) | 10 (22·2) | 72 (35·0) | 28 (30·8) | 20 (30·8) |
| IMP1 or p62 or Koc or p53 | 17 (26·6) | 25 (44·6) | 16 (35·6) | 78 (37·9) | 37 (40·7) | 24 (36·9) |
| IMP1 or p62 or Koc or p53 or c-myc | 25 (39·1) | 27 (48·2) | 17 (37·8) | 81 (39·3) | 40 (44·0) | 32 (49·2) |
| IMP1 or p62 or Koc or p53 or c-myc or cyclin B1 | 26 (40·6) | 36 (64·3) | 23 (51·1) | 95 (46·1) | 47 (51·6) | 35 (53·8) |
| IMP1 or p62 or Koc or p53 or c-myc or cyclin B1 or survivin | 28 (43·8) | 38 (67·9) | 23 (51·1) | 95 (46·1) | 48 (52·7) | 37 (56·9) |
a
Numbers in parenthesis are percentage of positive reactors in that cancer category. Positive reactors are defined as above the mean of 82 NHS ± 3 s.d. (from [68]).